New treatment in development for irritable bowel syndrome with constipation

December 08, 2020

Patients suffering from irritable bowel syndrome with constipation (IBS-C) have long needed an upgrade in treatment. Rapid-release, cramp-inducing doses of chenodeoxycholic acid (CDC) have previously shown promise in treating constipation, but further development has been hampered by the abdominal pain associated with the sudden release of CDC. Researchers at Brigham and Women's Hospital and the Massachusetts Institute of Technology (MIT) devised a plan to deliver CDC in a bilayered capsule, finding that this mode of delivery could decrease colon cramping and thus produce a better patient experience. In preclinical studies, the team found evidence that this bilayered delivery system has the potential to reduce cramping and provide constipation relief. Findings are published in Clinical and Translational Gastroenterology.

"We know bile acids are capable of helping with motility, but what has been attempted in the past is giving a bolus -- a boatload of bile acid all at once. This manifests in increased bowel movements, but also pain," said Giovanni Traverso, MD, PhD, of the Brigham's Division of Gastroenterology, Hepatology and Endoscopy and the Department of Mechanical Engineering at MIT. "Could we take this endogenous, natural product and deliver it in a way that overcomes this risk of contractions?"

The liver produces bile acids to aid in the digestive process, regulating intestinal motility, fluid homeostasis, and humoral activity. Bile acids, such as pro-motility CDC, have been previously studied in patients for their pro-motility effects and recognized to enhance water ingression and bowel motility. The challenge has been how to administer these in ways that minimize potential side effects; to accomplish this, researchers developed a bilayered delivery system.

The bilayered delivery mechanism was tested in swine models for half-life, colon cramping and whether it caused a similar dosage spike to single-layered delivery. Immediate release of the pill's surface layer established a healthy local concentration of CDC, which in turn offered enough colonic fluid to initiate the pill's second, slower-release layer of CDC. This biphasic release of CDC established a low-dose, long-lasting presence of bile acid over time, avoiding the dosage spike and decreasing cramping.

Several important limitations exist for this study, including lack of similar studies for comparison and shortcomings of the swine model; the team was not able to measure levels of abdominal pain in the swine model, and only rectal contractions were measured, as opposed to a full colonic evaluation.

Within the next 18 months, clinical trials will begin for the bilayered delivery of CDC to IBS-C patients, with pill production regulated by the team's newly founded Bilayer Therapeutics. Traverso envisions applications for this therapeutic far beyond IBS-C. Bile acids are involved in metabolic diseases, including diabetes and liver cytopathy.

"While further studies are necessary to demonstrate the therapeutic potential of these systems in humans, our findings suggest that controlled delivery of bile acids to the colon may represent a novel approach to treating gastrointestinal diseases such as constipation," said co-author Joshua Korzenik, MD, of the Brigham's Gastroenterology and Hepatology Division.
-end-
Funding for this work was provided by the Alexander von Humboldt Foundation (Feodor Lynen Fellowship) and the Department of Mechanical Engineering at Massachusetts Institute of Technology. Traverso, Korzenik and co-authors are co-inventors on a patent application describing the bile acid delivery systems described here within. Traverso, Korzenik and co-authors have a financial interest in Bilayer Therapeutics, Inc. This company is developing oral bile acid delivery systems.

Paper Cited: Steiger C et al. "Controlled Delivery of Bile Acids to the Colon" Clinical and Translational Gastroenterology DOI: 10.14309/ctg.0000000000000229

Brigham and Women's Hospital

Related Irritable Bowel Syndrome Articles from Brightsurf:

Giant spider provides promise of pain relief for irritable bowel syndrome
Molecules from the venom of one of the world's largest spiders could help University of Queensland-led researchers tailor pain blockers for people with irritable bowel syndrome (IBS).

An aspirin a day keeps the bowel doctor away
A regular dose of aspirin to reduce the risk of inherited bowel cancer lasts at least 10 years after stopping treatment, research has revealed.

Mindfulness program may benefit patients with irritable bowel syndrome
Adults with irritable bowel syndrome experienced fewer gastrointestinal symptoms after they participated in a mindfulness program meant to reduce stress.

The Lancet Gasteroenterology & Hepatology: First clinical trial finds probiotic treatment with dead bacteria is better than placebo at alleviating symptoms of irritable bowel syndrome
Probiotic bacteria that have been killed by heat can significantly improve symptoms of irritable bowel syndrome (IBS) compared to placebo, and are not associated with any safety risk, according to a new 12-week, randomized, double-blind, placebo-controlled clinical trial with 443 patients published in The Lancet Gastroenterology & Hepatology journal.

Are steroids used too much for patients with inflammatory bowel disease?
Steroid therapy is commonly used to treat acute attacks of the inflammatory bowel diseases ulcerative colitis and Crohn's disease; however, because it does not provide long-term benefits and it carries a risk of serious side effects, it should not be used to treat inflammatory bowel disease for more than three months.

New, noninvasive test for bowel diseases
Gut diseases such as inflammatory bowel disease (IBD) are increasingly prevalent worldwide, especially in industrialized countries.

HKBU discovers mechanisms underlying early life stress and irritable bowel syndrome
Researchers from Hong Kong Baptist University have found that the abnormal rise of a soluble protein called Nerve Growth Factor is a key factor linking early life stress to the development of irritable bowel syndrome.

Microbiome science may help doctors deliver more effective, personalized treatment to children with irritable bowel syndrome
To improve the treatment of children with irritable bowel syndrome (IBS), investigators have developed a sophisticated way to analyze the microbial and metabolic contents of the gut.

The Lancet Gastroenterology & Hepatology: Hypnotherapy could help relieve irritable bowel syndrome symptoms
Peer-reviewed / Randomised Controlled Trial / People Gut-directed hypnotherapy delivered by psychologists appears as effective in group or individual sessions, potentially offering a new treatment option for irritable bowel syndrome in primary and secondary care

Early source of irritable bowel syndrome discovered
Michigan State University scientists have identified an early cause of intestinal inflammation, one of the first stages of inflammatory bowel disease and irritable bowel syndrome, which afflict around 11 percent of the world's population.

Read More: Irritable Bowel Syndrome News and Irritable Bowel Syndrome Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.